ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, March 18, 2016 --

What:  
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, James Sapirstein, President and Chief Executive Officer, will ring the Closing Bell. 

Where: 
Nasdaq MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When: 
Monday, March 21, 2016 – 3:45 p.m. to 4:00 p.m. ET     

ContraVir Pharmaceuticals Media Contact: 
Claire Sojda
(212) 375-2686 
[email protected]

Nasdaq MarketSite: 
Emily Pan
(646) 441-5120 
[email protected]

Feed Information: 
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media: 

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: 
http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: 
http://instagram.com/nasdaq

For livestream of ceremonies and events visit our YouTube Page: 
http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page at: 
http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit our Tumblr Page: 
http://nasdaq.tumblr.com/

Webcast:
A LiveStream of the Nasdaq Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead clinical drug, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir for the Hepatitis B virus.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal and bone side effects.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and nearly 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-